NVIDIA, Roche & Danone: This Week's Top Healthcare Stories

NVIDIA: How are 70% of Healthcare Organisations Using AI?

NVIDIA is planning to support the advance of healthcare with AI, aiming to adapt across science, robotics and intelligent agents. 

In NVIDIA’s most recent “State of AI in Healthcare and Life Sciences” survey report, it finds the healthcare industry is transitioning from AI experimentation to full-scale implementation, achieving ROI in key areas such as medical imaging and drug discovery.

From the lab and genomic testing to diagnostic imaging, the company is planning to empower healthcare partners to “accelerate discovery, improve care and drive innovation with scalable, high-performance solutions.”

How Danone Supports Consumer Protein Intake

Danone’s annual results hint at a turning point for the dairy market.

While its broader yogurt portfolio remains a “work in progress,” the company’s high-protein lines – Oikos, GetPRO and HiPRO – continued to post double-digit growth throughout 2025.

CEO Antoine de Saint-Affrique noted that nearly all of Danone’s North American expansion was supported by the “winning momentum” of its high-protein products, which helped offset weaker performance in other dairy segments. 

Roche: Innovating Healthcare with Sustainability and Tech

Founded more than 125 years ago, Roche has grown into one of the world’s largest biotech companies and a leading provider of in-vitro diagnostics, delivering innovative solutions across major disease areas.

The company remains deeply committed to its patients, partners, employees and stakeholders, driving its mission to advance science and improve healthcare access globally.

Through its combined strengths in Pharmaceuticals and Diagnostics, Roche continues to create meaningful impact by improving patient outcomes and supporting the professionals who care for them.

Innovation and a focus on a healthier future remain at the core of Roche’s purpose.

Why is Merck Restructuring Healthcare & Oncology for Growth?

Merck & Co, known as MSD outside the United States and Canada, has announced a major evolution of its Human Health organisational structure aimed at strengthening commercial execution across a broad and increasingly diverse portfolio. 

The move helps to reflect the company’s commitment to sustaining leadership in key therapeutic areas while preparing for a wave of anticipated product launches. 

With a robust late-stage pipeline and numerous Phase 3 trials underway, the restructuring is designed to align strategy, operations and patient access efforts more closely. 

The changes underscore Merck’s focus on delivering innovative medicines and long-term value in a rapidly evolving global healthcare landscape.

Is 2026 the Year of Healthcare M&A Growth and AI Innovation?

According to PwC, health industry dealmakers are entering 2026 with renewed confidence and a sense of strategic urgency. 

After navigating two years of economic volatility and regulatory shifts, the merger and acquisition (M&A) environment is poised for acceleration rather than stabilisation. 

Buyers are increasingly focused on resilient assets, value creation and consumer-centric, tech-enabled care, while global innovation hubs are reshaping the competitive landscape. 

As a result, leading players are making bold portfolio moves that position them for a rapidly evolving healthcare ecosystem.